Management of pneumocystis jirovecii pneumonia in kidney transplantation to prevent further outbreak

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Volumn 9, Issue , 2015, Pages 81-90

  Goto, Norihiko ^a   Futamura, Kenta ^a   Okada, Manabu ^a   Yamamoto, Takayuki ^a   Tsujita, Makoto ^a   Hiramitsu, Takahisa ^a   Narumi, Shunji ^a   Watarai, Yoshihiko ^a  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Infection control; Kidney transplantation; Outbreak; Pneumocystis jirovecii pneumonia; Prophylaxis

Indexed keywords

ATOVAQUONE; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; DAPSONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLATE MOFETIL; PENTAMIDINE; PREDNISONE; RAPAMYCIN; RITUXIMAB;

ADJUVANT THERAPY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENVIRONMENTAL EXPOSURE; EPIDEMIC; FOCAL GLOMERULOSCLEROSIS; FUNGAL COLONIZATION; FUNGUS TRANSMISSION; GENOTYPE; GRAFT FAILURE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION CONTROL; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MACROPHAGE; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PROGNOSIS; REINFECTION; REVIEW; SERODIAGNOSIS; STAFF TRAINING; STAINING; THORAX RADIOGRAPHY;

EID: 84947426905     PISSN: 11795484     EISSN: 11795484     Source Type: Journal    
DOI: 10.4137/CCRPM.S23317     Document Type: Review

References (138)

1. Vanek J, Jirovec O. [Parasitic pneumonia. Interstitial plasma cell pneumonia of premature, caused by Pneumocystis carinii]. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg. 1952;158(1-2):120-7
2. Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36(6):2004-9
3. Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med. 1974;80(1):83-93
4. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis. 2007;44(9):1143-9
5. Sassi M, Ripamonti C, Mueller NJ, et al. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. Clin Infect Dis. 2012;54(10):1437-44
6. Le Gal S, Damiani C, Rouille A, et al. A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis. 2012;54(7): e62-71
7. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation. 2009;88(3):380-5
8. de Boer MG. Linking Pneumocystis epidemiology, transmission, and virulence. Clin Infect Dis. 2012;54(10):1445-7
9. Nankivell BJ, Firacative C, Kable K, Chen SC, Meyer W. Molecular epidemiology linking multihospital clusters of opportunistic Pneumocystis jirovecii pneumonia. Clin Infect Dis. 2013;57(7):1058-9
10. Cruz RE, Macedo AM, Barnabe C, et al. Further genetic characterization of the two Trypanosoma cruzi Berenice strains (Be-62 and Be-78) isolated from the first human case of Chagas disease (Chagas, 1909). Acta Trop. 2006;97(3):239-46
11. Carini A. Formas des eschizogonia do Trypanosoma lewisi. Soc Med Cir São Paulo. 1910;16:204
12. Sajadi MM, Fantry GT, Fantry LE. A Czech researcher and Pneumocystis. Clin Infect Dis. 2004;39(2):70-1
13. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334(6182):519-22
14. Schildgen V, Mai S, Khalfaoui S, et al. Pneumocystis jirovecii can be productively cultured in differentiated CuFi-8 airway cells. MBio. 2014;5(3):e1186-14
15. Frenkel JK. Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): a critical historical overview. J Eukaryot Microbiol. 1999;46(5):89s-92s
16. Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183(3):388-95
17. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-33
18. Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am. 2010;24(1):107-38
19. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487-98
20. Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jirovecii pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014;127(12):1242.e11-7
21. Maini R, Henderson KL, Sheridan EA, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-10. Emerg Infect Dis. 2013;19(3):386-92
22. Borstnar S, Lindic J, Tomazic J, et al. Pneumocystis jirovecii pneumonia in renal transplant recipients: a national center experience. Transplant Proc. 2013;45(4):1614-7
23. Leth S, Jensen-Fangel S, Ostergaard L, Rostved AA, Jespersen B, Sogaard OS. Pneumocystis jirovecii pneumonia in patients with end-stage renal disease: a comparison with the general population. Scand J Infect Dis. 2014;46(10): 704-11
24. Chapman JR, Marriott DJ, Chen SC, MacDonald PS. Post-transplant Pneumocystis jirovecii pneumonia - a re-emerged public health problem? Kidney Int. 2013;84(2):240-3
25. Aliouat-Denis CM, Martinez A, Aliouat el M, Pottier M, Gantois N, Dei-Cas E. The Pneumocystis life cycle. Mem Inst Oswaldo Cruz. 2009;104(3):419-26
26. Gigliotti F, Harmsen AG, Haidaris CG, Haidaris PJ. Pneumocystis carinii is not universally transmissible between mammalian species. Infect Immun. 1993; 61(7):2886-90
27. Wakefield AE. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora. J Clin Microbiol. 1996;34(7):1754-9
28. Dei-Cas E. Pneumocystis infections: the iceberg? Med Mycol. 2000;38(suppl 1): 23-32
29. Cushion MT, Linke MJ, Ashbaugh A, et al. Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One. 2010;5(1):e8524
30. Martinez A, Halliez MC, Aliouat el M, et al. Growth and airborne transmission of cell-sorted life cycle stages of Pneumocystis carinii. PLoS One. 2013;8(11):e79958
31. Wakefield AE, Pixley FJ, Banerji S, et al. Amplification of mitochondrial ribosomal RNA sequences from Pneumocystis carinii DNA of rat and human origin. Mol Biochem Parasitol. 1990;43(1):69-76
32. Parobek CM, Jiang LY, Patel JC, et al. Multilocus microsatellite genotyping array for investigation of genetic epidemiology of Pneumocystis jirovecii. J Clin Microbiol. 2014;52(5):1391-9
33. Lee CH, Helweg-Larsen J, Tang X, et al. Update on Pneumocystis carinii f. sp. hominis typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. J Clin Microbiol. 1998;36(3):734-41
34. Gits-Muselli M, Peraldi MN, de Castro N, et al. New short tandem repeat-based molecular typing method for Pneumocystis jirovecii reveals intrahospital transmission between patients from different wards. PLoS One. 2015;10(5):e0125763
35. Marcotte H, Levesque D, Delanay K, et al. Pneumocystis carinii infection in transgenic B cell-deficient mice. J Infect Dis. 1996;173(4):1034-7
36. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;61(1):35-41
37. Lund FE, Schuer K, Hollifield M, Randall TD, Garvy BA. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody. J Immunol. 2003;171(3):1423-30
38. Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest. 1997;99(9):2110-7
39. Lasbury ME, Durant PJ, Ray CA, Tschang D, Schwendener R, Lee CH. Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with Pneumocystis pneumonia. J Immunol. 2006;176(11):6443-53
40. Wakefield AE, Lindley AR, Ambrose HE, Denis CM, Miller RF. Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis. 2003;187(6):901-8
41. Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis. 2004;10(10):1766-73
42. Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect. 2002;4(1):95-103
43. Bartlett MS, Lee CH, Lu JJ, et al. Pneumocystis carinii detected in air. J Eukaryot Microbiol. 1994;41(5):75s
44. Olsson M, Sukura A, Lindberg LA, Linder E. Detection of Pneumocystis carinii DNA by filtration of air. Scand J Infect Dis. 1996;28(3):279-82
45. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis. 2008;197(1):10-7
46. An CL, Gigliotti F, Harmsen AG. Exposure of immunocompetent adult mice to Pneumocystis carinii f. sp. muris by cohousing: growth of P. carinii f. sp. muris and host immune response. Infect Immun. 2003;71(4):2065-70
47. Gigliotti F, Harmsen AG, Wright TW. Characterization of transmission of Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice. Infect Immun. 2003;71(7):3852-6
48. Mori S, Cho I, Sugimoto M. A cluster of Pneumocystis jirovecii infection among outpatients with rheumatoid arthritis. J Rheumatol. 2010;37(7):1547-8
49. Le Gal S, Pougnet L, Damiani C, et al. Pneumocystis jirovecii in the air surrounding patients with Pneumocystis pulmonary colonization. Diagn Microbiol Infect Dis. 2015;82(2):137-42
50. Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009;301(24):2578-85
51. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267(6):832-7
52. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71(1):5-13
53. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17(4):770-82, table of contents
54. Eitner F, Hauser IA, Rettkowski O, et al. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant. 2011;26(6): 2013-7
55. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation. 2009;88(1):135-41
56. Schurmann M, Schurmann D, Schindler R, et al. Impaired thymic function and CD4+ T lymphopenia, but not mannose-binding lectin deficiency, are risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients. Transpl Immunol. 2013;28(4):159-63
57. Debourgogne A, Favreau S, Ladriere M, Bourry S, Machouart M. Characteristics of Pneumocystis pneumonia in Nancy from January 2007 to April 2011 and focus on an outbreak in nephrology. J Mycol Med. 2014;24(1):19-24
58. Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis. 1996;22(6):920-5
59. Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis. 2003;5(2):84-93
60. Kumar D, Gourishankar S, Mueller T, et al. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis. 2009;11(2):167-70
61. Deborska-Materkowska D, Kozinska-Przybyl O, Mikaszewska-Sokolewicz M, Durlik M. Fatal late-onset Pneumocystis pneumonia after rituximab: administration for posttransplantation recurrence of focal segmental glomerulosclerosis - case report. Transplant Proc. 2014;46(8):2908-11
62. Lufft V, Kliem V, Behrend M, Pichlmayr R, Koch KM, Brunkhorst R. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation. 1996;62(3):421-3
63. Orlando G, Tariciotti L, Manzia TM, et al. Ab initio calcineurin inhibitor-based monotherapy immunosuppression after liver transplantation reduces the risk for Pneumocystis jirovecii pneumonia. Transpl Infect Dis. 2010;12(1): 11-5
64. Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis. 2011;13(6):551-8
65. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis. 2001;33(8):1397-405
66. de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis. 2011;13(6): 559-69
67. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol. 2008;46(3):966-71
68. Arichi N, Kishikawa H, Mitsui Y, et al. Cluster outbreak of Pneumocystis pneumonia among kidney transplant patients within a single center. Transplant Proc. 2009;41(1):170-2
69. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601-14
70. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest. 2007;131(4):1173-80
71. Cushion MT, Beck JM. Summary of Pneumocystis research presented at the 7th International Workshop on Opportunistic Protists. J Eukaryot Microbiol. 2001;48(suppl):101s-5s
72. Bigby TD. Diagnosis of Pneumocystis carinii pneumonia. How invasive? Chest. 1994;105(3):650-2
73. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5(4):298-308
74. Cregan P, Yamamoto A, Lum A, VanDerHeide T, MacDonald M, Pulliam L. Comparison of four methods for rapid detection of Pneumocystis carinii in respiratory specimens. J Clin Microbiol. 1990;28(11):2432-6
75. Bedrossian CW, Mason MR, Gupta PK. Rapid cytologic diagnosis of Pneumocystis: a comparison of effective techniques. Semin Diagn Pathol. 1989;6(3): 245-61
76. Gal AA, Koss MN, Strigle S, Angritt P. Pneumocystis carinii infection in the acquired immune deficiency syndrome. Semin Diagn Pathol. 1989;6(3):287-99
77. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140(5):1204-9
78. Kovacs JA, Ng VL, Masur H, et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;318(10):589-93
79. Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J. Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest. 2009;135(3):655-61
80. Ribes JA, Limper AH, Espy MJ, Smith TF. PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity. J Clin Microbiol. 1997;35(4):830-5
81. Jiancheng W, Minjun H, Yi-jun A, et al. Screening Pneumocystis carinii pneumonia in non-HIV-infected immunocompromised patients using polymerase chain reaction. Diagn Microbiol Infect Dis. 2009;64(4):396-401
82. Larsen HH, Masur H, Kovacs JA, et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol. 2002;40(2):490-4
83. Huggett JF, Taylor MS, Kocjan G, et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax. 2008;63(2):154-9
84. Alanio A, Desoubeaux G, Sarfati C, et al. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect. 2011;17(10): 1531-7
85. Flori P, Bellete B, Durand F, et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol. 2004; 53(pt 7):603-7
86. Larsen HH, Huang L, Kovacs JA, et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis. 2004;189(9): 1679-83
87. Fillaux J, Malvy S, Alvarez M, et al. Accuracy of a routine real-time PCR assay for the diagnosis of Pneumocystis jirovecii pneumonia. J Microbiol Methods. 2008;75(2):258-61
88. Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000;28(12):E63
89. Nakashima K, Aoshima M, Ohkuni Y, Hoshino E, Hashimoto K, Otsuka Y. Loop-mediated isothermal amplification method for diagnosing Pneumocystis pneumonia in HIV-uninfected immunocompromised patients with pulmonary infiltrates. J Infect Chemother. 2014;20(12):757-61
90. Uemura N, Makimura K, Onozaki M, et al. Development of a loop-mediated isothermal amplification method for diagnosing Pneumocystis pneumonia. J Med Microbiol. 2008;57(pt 1):50-7
91. Marty FM, Koo S. Role of (1--.3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol. 2009;47(suppl 1):S233-40
92. Pazos C, Ponton J, Del Palacio A. Contribution of (1-.3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005;43(1):299-305
93. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-21
94. Matsumoto Y, Matsuda S, Tegoshi T. Yeast glucan in the cyst wall of Pneumocystis carinii. J Protozool. 1989;36(1):21s-2s
95. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1--.3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol. 1996;3(2):197-9
96. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-beta-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50(1):7-15
97. Obayashi T, Yoshida M, Mori T, et al. Plasma (1--.3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet. 1995;345(8941):17-20
98. Mori T, Ikemoto H, Matsumura M, et al. Evaluation of plasma (1--.3)-beta-D-glucan measurement by the kinetic turbidimetric Limulus test, for the clinical diagnosis of mycotic infections. Eur J Clin Chem Clin Biochem. 1997;35(7): 553-60
99. Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1--.3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009;49(7):1128-31
100. Karageorgopoulos DE, Qu JM, Korbila IP, Zhu YG, Vasileiou VA, Falagas ME. Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect. 2013;19(1):39-49
101. Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol. 2006;16(5):282-8
102. de Boer MG, Gelinck LB, van Zelst BD, et al. beta-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect. 2011;62(1):93-100
103. Nakamura H, Tateyama M, Tasato D, et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med. 2009; 48(4):195-202
104. Matsumura Y, Ito Y, Iinuma Y, et al. Quantitative real-time PCR and the (1--.3)-beta-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. Clin Microbiol Infect. 2012;18(6):591-7
105. Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis. 2011;5(1):41-59
106. DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest. 1987;91(3): 323-7
107. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):272-9
108. Naderer O, Nafziger AN, Bertino JS Jr. Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother. 1997;41(11):2466-70
109. Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis. 2009;41(11-12):862-8
110. Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;4:Cd006150
111. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3):S1-155
112. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113(5):1215-24
113. Burke BA, Good RA. Pneumocystis carinii infection. Medicine (Baltimore). 1973;52(1):23-51
114. Bollee G, Sarfati C, Thiery G, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132(4):1305-10
115. Moon SM, Kim T, Sung H, et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother. 2011;55(10):4613-8
116. Zahar JR, Robin M, Azoulay E, Fieux F, Nitenberg G, Schlemmer B. Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin Infect Dis. 2002;35(8):929-34
117. Lemiale V, Debrumetz A, Delannoy A, Alberti C, Azoulay E. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res. 2013;14:87
118. McKinnell JA, Cannella AP, Injean P, Gregson A. Adjunctive glucocorticoid therapy for non-HIV-related Pneumocystis carinii pneumonia (NH-PCP). Am J Transplant. 2014;14(4):982-3
119. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156(2):177-88
120. Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis. 1998;27(1):191-204
121. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant. 2002;17(suppl 4):36-9
122. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4): 299-311
123. Batiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant. 2002;16(1):1-8
124. Morris A, Kingsley LA, Groner G, Lebedeva IP, Beard CB, Norris KA. Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS. 2004;18(5):793-8
125. Fritzsche C, Riebold D, Fuehrer A, et al. Pneumocystis jirovecii colonization among renal transplant recipients. Nephrology (Carlton). 2013;18(5):382-7
126. Magne D, Angoulvant A, Botterel F, et al. Pneumocystosis: a network survey in the Paris area 2003-2008. Eur J Clin Microbiol Infect Dis. 2011;30(5):673-5
127. Tamai K, Tachikawa R, Tomii K, et al. Prognostic value of bronchoalveolar lavage in patients with non-HIV Pneumocystis pneumonia. Intern Med. 2014;53(11):1113-7
128. Kim SJ, Lee J, Cho YJ, et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect. 2014;69(1):88-95
129. Ainoda Y, Hirai Y, Fujita T, Isoda N, Totsuka K. Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia. J Infect Chemother. 2012;18(5):722-8
130. Asai N, Motojima S, Ohkuni Y, et al. Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection. J Infect Chemother. 2012;18(6):898-905
131. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000;118(3):704-11
132. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis. 2002;34(8):1098-107
133. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21(2):246-51
134. Gianella S, Haeberli L, Joos B, et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl Infect Dis. 2010;12(1):1-10
135. Phipps LM, Chen SC, Kable K, et al. Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients. Transplantation. 2011;92(12):1327-34
136. Struijk GH, Gijsen AF, Yong SL, et al. Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation. Nephrol Dial Transplant. 2011;26(10): 3391-8
137. Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35(10 suppl 2):S65-164
138. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med. 2000;342(19):1416-29